

Novartis, Aster ink MoU to advance digital transformation & clinical research

03 February 2022 | News

The digital transformation initiatives will work on boosting the digital healthcare strategy as well



Novartis has signed a Memorandum of Understanding (MoU) with Aster DM Healthcare, one of the largest integrated healthcare providers in the Middle East. The MoU will enable Aster to access Novartis' advanced therapy platforms and data science to further strengthen treatment outcomes for patients in UAE and beyond.

The collaboration focused on digital transformation and clinical research will aim to identify current gaps in patient care and introduce extensive medical programmes using innovative data platforms and data syndicated designs.

This is in alignment with Aster's long-term plan to integrate clinical research and digital transformation into its operations in UAE and beyond which will have a significant impact on the clinical outcome delivery for patients,

As a part of the collaboration, Novartis will enable data generation, ideation, and impactful decision making for Aster DM Healthcare's clinical research program. The organizations have plans to initiate a series of workshops, trainings, and educational activities, which will assist Aster to commence its activities on clinical research.